Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical ModelsLars D. Engstrom, James G. Christensen, Matthew Lee et al.|Clinical Cancer Research|2017Cited by 147
Targeting MET and EGFR crosstalk signaling in triple-negative breast cancersErik S. Linklater, Carrie R. Graveel|Oncotarget|2016Cited by 80